目前对二甲双胍在糖尿病高血糖控制方面作用的认识。
Current understanding of metformin effect on the control of hyperglycemia in diabetes.
作者信息
An Hongying, He Ling
机构信息
Divisions of Metabolism and EndocrinologyDepartment of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, Maryland 21287, USA.
Divisions of Metabolism and EndocrinologyDepartment of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, Maryland 21287, USA
出版信息
J Endocrinol. 2016 Mar;228(3):R97-106. doi: 10.1530/JOE-15-0447. Epub 2016 Jan 7.
Abstract
Metformin is a first-line oral anti-diabetic agent that has been used clinically to treat patients with type 2 diabetes for over 60 years. Due to its efficacy in therapy and affordable price, metformin is taken by more than 150 million people each year. Metformin improves hyperglycemia mainly through the suppression of hepatic gluconeogenesis along with the improvement of insulin signaling. However, its mechanism of action remains partially understood and controversial, especially in regard to the role of AMPK in metformin's action and the mechanism of AMPK activation. In this review, we discuss recent advances in the understanding of metformin's suppression of hepatic glucose production and the mechanism related to the improvement of insulin signaling.
摘要
二甲双胍是一种一线口服抗糖尿病药物，已在临床上用于治疗2型糖尿病患者60多年。由于其治疗效果显著且价格亲民，每年有超过1.5亿人服用二甲双胍。二甲双胍主要通过抑制肝糖异生以及改善胰岛素信号传导来改善高血糖。然而，其作用机制仍部分未明且存在争议，特别是关于AMPK在二甲双胍作用中的作用以及AMPK激活机制。在本综述中，我们讨论了在理解二甲双胍抑制肝葡萄糖生成以及与改善胰岛素信号传导相关机制方面的最新进展。
相似文献
1
Current understanding of metformin effect on the control of hyperglycemia in diabetes.
J Endocrinol. 2016 Mar;228(3):R97-106. doi: 10.1530/JOE-15-0447. Epub 2016 Jan 7.
2
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
Nature. 2014 Jun 26;510(7506):542-6. doi: 10.1038/nature13270. Epub 2014 May 21.
3
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.
Nat Rev Endocrinol. 2019 Oct;15(10):569-589. doi: 10.1038/s41574-019-0242-2. Epub 2019 Aug 22.
4
Metformin--mode of action and clinical implications for diabetes and cancer.
Nat Rev Endocrinol. 2014 Mar;10(3):143-56. doi: 10.1038/nrendo.2013.256. Epub 2014 Jan 7.
5
Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.
Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205. doi: 10.2174/1871530315666150316124019.
6
The target of metformin in type 2 diabetes.
N Engl J Med. 2014 Oct 16;371(16):1547-8. doi: 10.1056/NEJMcibr1409796.
7
Angelica gigas Ameliorates Hyperglycemia and Hepatic Steatosis in C57BL/KsJ-db/db Mice via Activation of AMP-Activated Protein Kinase Signaling Pathway.
Am J Chin Med. 2016;44(8):1627-1638. doi: 10.1142/S0192415X16500919. Epub 2016 Nov 16.
8
A proposal for the locus of metformin's clinical action: potentiation of the activation of pyruvate kinase by fructose-1,6-diphosphate.
Med Hypotheses. 1999 Feb;52(2):89-93. doi: 10.1054/mehy.1997.0597.
9
Metformin: from mechanisms of action to therapies.
Cell Metab. 2014 Dec 2;20(6):953-66. doi: 10.1016/j.cmet.2014.09.018. Epub 2014 Oct 30.
10
Beneficial effect of betulinic acid on hyperglycemia via suppression of hepatic glucose production.
J Agric Food Chem. 2014 Jan 15;62(2):434-42. doi: 10.1021/jf4030739. Epub 2013 Dec 30.
引用本文的文献
1
Advancement of artificial intelligence based treatment strategy in type 2 diabetes: A critical update.
J Pharm Anal. 2025 Jun;15(6):101305. doi: 10.1016/j.jpha.2025.101305. Epub 2025 Apr 10.
2
Mechanistic insight into nanomedicine for polycystic ovary syndrome.
Mol Biol Rep. 2025 Jun 21;52(1):618. doi: 10.1007/s11033-025-10709-7.
3
Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis.
PLoS One. 2025 May 5;20(5):e0321032. doi: 10.1371/journal.pone.0321032. eCollection 2025.
4
Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients.
BMC Pharmacol Toxicol. 2025 Feb 27;26(1):45. doi: 10.1186/s40360-025-00882-7.
5
The Gut Microbiota-Related Antihyperglycemic Effect of Metformin.
Pharmaceuticals (Basel). 2025 Jan 6;18(1):55. doi: 10.3390/ph18010055.
6
Efficacy and safety of visepegenatide as an add-on therapy to metformin in patients with type 2 diabetes: a randomised, double-blind, parallel, placebo-controlled, phase 3 study.
Lancet Reg Health West Pac. 2024 Oct 3;51:101197. doi: 10.1016/j.lanwpc.2024.101197. eCollection 2024 Oct.
7
Metformin prevents the onset and progression of intervertebral disc degeneration: New insights and potential mechanisms (Review).
Int J Mol Med. 2024 Aug;54(2). doi: 10.3892/ijmm.2024.5395. Epub 2024 Jul 4.
8
Metformin Monotherapy With and Without Lifestyle Changes Affects Anthropometric Parameters, Blood Pressure, Blood Glucose, and Lipid Profile in Indian Patients With Newly Diagnosed Type 2 Diabetes.
Cureus. 2024 Jun 11;16(6):e62131. doi: 10.7759/cureus.62131. eCollection 2024 Jun.
9
Anti-Inflammatory Potential of the Anti-Diabetic Drug Metformin in the Prevention of Inflammatory Complications and Infectious Diseases Including COVID-19: A Narrative Review.
Int J Mol Sci. 2024 May 10;25(10):5190. doi: 10.3390/ijms25105190.
10
Endocannabinoid biosynthetic enzymes regulate pain response via LKB1-AMPK signaling.
Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2304900120. doi: 10.1073/pnas.2304900120. Epub 2023 Dec 18.
本文引用的文献
1
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats.
Nat Med. 2015 May;21(5):506-11. doi: 10.1038/nm.3787. Epub 2015 Apr 6.
2
Metformin action: concentrations matter.
Cell Metab. 2015 Feb 3;21(2):159-162. doi: 10.1016/j.cmet.2015.01.003.
3
Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex.
J Biol Chem. 2015 Feb 6;290(6):3793-802. doi: 10.1074/jbc.M114.604421. Epub 2014 Dec 23.
4
Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK).
J Biol Chem. 2014 Jul 25;289(30):20435-46. doi: 10.1074/jbc.M114.567271.
5
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.
Nature. 2014 Jun 26;510(7506):542-6. doi: 10.1038/nature13270. Epub 2014 May 21.
6
Potential biomarker of metformin action.
J Endocrinol. 2014 Jun;221(3):363-9. doi: 10.1530/JOE-14-0084. Epub 2014 Mar 17.
7
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin.
Nat Med. 2013 Dec;19(12):1649-54. doi: 10.1038/nm.3372. Epub 2013 Nov 3.
8
Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers.
J Nutr. 2013 Dec;143(12):1872-81. doi: 10.3945/jn.113.179549. Epub 2013 Oct 16.
9
AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation.
Cell Metab. 2013 Oct 1;18(4):556-66. doi: 10.1016/j.cmet.2013.08.019.
10
Gut microbiota from twins discordant for obesity modulate metabolism in mice.
Science. 2013 Sep 6;341(6150):1241214. doi: 10.1126/science.1241214.
Zotero 插件